INOVIO Showcases Innovations at Major Scientific Conference
INOVIO to Present at Important Scientific Conference
INOVIO (NASDAQ: INO), a biotechnology company at the forefront of developing DNA medicines, announces its participation in a significant scientific conference to share advancements in treatments for HPV-related diseases, cancer, and other infectious diseases.
Conference Presentation Details
At the World Congress of Electroporation, INOVIO will feature an oral presentation by Trevor Smith, the Vice President of Preclinical R&D. His presentation will focus on "Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA electroporation technology." The presentation is scheduled for September 18, 2024, from 3:20 PM to 3:35 PM CET.
Accessing the Research
The insights shared during this presentation are expected to enhance understanding of innovative techniques in the biotechnology sector. Following the event, attendees can access the abstract from INOVIO's website, further illustrating the neat breakthroughs discussed during the conference.
About INOVIO
INOVIO is dedicated to pioneering DNA-based treatments designed to empower the body's immune system against various health challenges, including HPV-related complications and cancer. Their technology focuses on creating effective and safe methods for delivering DNA medicines, fostering the body’s ability to create its own disease-fighting agents through advanced design and delivery techniques.
Company's Vision and Mission
With a vision that prioritizes health innovation, INOVIO aims to continue leading in the biotechnology landscape. Their commitment to research and development remains unwavering, seeking patterns in how DNA medicines can be further optimized for patient care and safety.
Contact Information
For media inquiries, please reach out to Jennie Willson at (267) 429-8567. Investors can contact Thomas Hong at (267) 440-4298 for more insights into the company’s operations and future plans.
Frequently Asked Questions
What is the focus of INOVIO's presentation at the conference?
INOVIO will discuss advancements in DNA medicines, specifically the development of synthetic DNA-encoded antibodies using electroporation technology.
When is the presentation scheduled?
The presentation is scheduled for September 18, 2024, from 3:20 PM to 3:35 PM CET.
Who is presenting on behalf of INOVIO?
Trevor Smith, the VP of Preclinical R&D at INOVIO, will deliver the presentation.
How can I access the conference abstract?
Those interested can find the abstract on INOVIO's official website after the conference.
Where can I find more information about INOVIO?
More information can be found by visiting INOVIO's website, where they detail their projects and innovations in DNA medicines.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- TAG Forms Dedicated Q-SYS Team to Drive AV Solutions Forward
- Innovent Showcases Clinical Success of IBI354 Across Various Cancers
- CompoSecure's CEO Sells Shares: What It Means for Investors
- Michele Logan's Recent Stock Sale: Implications for CompoSecure
- Recent Developments at Mastercard: A Comprehensive Overview
- Recent Insider Sales and Strategic Acquisition at P10 Inc.
- Insider Confidence: Terns Pharmaceuticals Sees Major Stock Purchase
- Analyzing the Growth Potential of Major Stocks in Tech
- UAW Union Gears Up for Potential Strike Votes at Stellantis
- Sunrun Successfully Prices $365M Securitization Offering
Recent Articles
- Allison Transmission and LiuGong Collaborate for Mining Innovation
- GeoVax Labs Adjusts Meeting Plans, Sets New Date for Stockholders
- Roku Inc. Secures $300 Million Credit Facility for Growth
- Kytopen's Flowfect Tx™ Platform Sets New Standard for Cell Engineering
- Challenges Ahead for Dunxin Financial Following Delisting
- Lockheed Martin Secures $297M Contract for NOAA Lightning Mapper
- Mondee Boosts Growth Prospects with $15M Credit Secured
- MEM Enhances Midwest Operations with Exciting Brand Launch
- Cousins Properties Declares Q3 Dividend of $0.32 Per Share
- Truist Securities Increases Cintas Price Target to $225
- Guayakí Yerba Mate and LAFC Join Forces to Transform Soccer
- D-Market's Strategic Board Expansion Amidst Financial Decisions
- Aflac Donates 40 Special Ducks to Children’s Hospital Patients
- Interactive Strength Inc. Restructures Debt through Equity Swap
- Emergent BioSolutions Declares Strategic Equity Moves Today
- Capricor Therapeutics Boosts Market Confidence with New Deals
- Bridgette P. Heller's Recent Sell-off: Impacts on DexCom's Market
- Cytokinetics Executive Sells Stock Amid Positive Drug Developments
- Michael Davis Increases Stake in Cyanotech with $8,200 Purchase
- Air Industries Group Insider Transaction and Recent Developments
- Neurocrine Biosciences: Executive Stock Sale and Future Prospects
- IBEX Ltd Insider Transactions Highlight Financial Performance
- Steve Cohen Shifts Focus to Growth at Point72 Asset Management
- BlackRock and Microsoft Unite for a Major AI Investment Fund
- Introducing $BBT Token: Revolutionizing Blockchain Gaming Experience
- Indivior PLC Investors Can Now Seize Class Action Opportunity
- Understanding the Latest Developments with Transocean Ltd. RIG
- Biden Administration Plans Significant Oil Purchase to Replenish Reserves
- Emerie.ai: Transforming Customer Experience in FinTech
- Casella Waste Systems Initiates $400 Million Stock Offering
- RadNet, Inc. Showcases Innovations at Upcoming Virtual Conference
- Structure Therapeutics Enhances Leadership Team for Growth
- Resolute Holdings Expands Presence with CompoSecure Acquisition
- GOREWEAR Launches Innovative Lineup for Running and Cycling
- DXC Technology Company Investors Encouraged to Act Before Deadline
- Kairos Pharma Celebrates Successful $6.2 Million IPO
- Toll Brothers Declares Quarterly Dividend for Shareholders
- Massive Bitcoin Profits and the Whales' Predictive Moves
- Americold Realty Trust Sets Upcoming Earnings Conference Date
- Chanson International Secures $7.274 Million in Recent Offering
- Mondee Secures $15 Million Credit, Extends Key Financial Deadlines
- Strategic Cost Management: Blink Charging's Path to Growth
- Teamsters Secure Significant Wage and Benefit Gains
- Resignation of Independent Directors from 23andMe's Board
- Rosen Law Firm Urges Investors to Act Now for Moderna Case
- ISS A/S Shareholding Changes: Insights on Major Transactions
- Resignation of 23andMe Board Directors Sparks Strategic Debate
- Toro Company Announces Dividend: What's Next for Investors?
- AG Growth International Inc. Releases Q3 2024 Dividend Details
- ACRES Commercial Realty Corp. Announces Cash Dividends for Q3